Published in MAGMA on December 15, 2006
Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes (2009) 2.68
Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn (2008) 2.51
Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int (2014) 1.80
1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol (2008) 1.51
Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia (2009) 1.50
Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes (2008) 1.20
Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics (2011) 1.19
A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in 1H NMR metabonomic data. BMC Bioinformatics (2007) 0.88
Metabolomics approach for analyzing the effects of exercise in subjects with type 1 diabetes mellitus. PLoS One (2012) 0.83
Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study). Metabolomics (2011) 0.80
Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. JCI Insight (2016) 0.78
Metabonomics analysis of plasma reveals the lactate to cholesterol ratio as an independent prognostic factor of short-term mortality in acute heart failure. PLoS One (2013) 0.78
Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics. Diseases (2016) 0.75
Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov (2003) 4.46
Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem (2005) 4.14
Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med (2002) 3.91
Type 1 diabetes. Lancet (2006) 3.61
Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature (2006) 3.45
Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes (2003) 2.79
Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care (2005) 2.26
NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed (2005) 2.15
Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci (2004) 1.89
Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia (2003) 1.84
Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer (2005) 1.84
Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers (2004) 1.79
The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Philos Trans R Soc Lond B Biol Sci (2006) 1.63
Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal Chem (2006) 1.61
Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr Opin Chem Biol (2003) 1.57
Use of relaxation-edited one-dimensional and two dimensional nuclear magnetic resonance spectroscopy to improve detection of small metabolites in blood plasma. Anal Biochem (2004) 1.51
Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med (2006) 1.49
The role of analytical sciences in medical systems biology. Curr Opin Chem Biol (2004) 1.47
Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. Diabetes (2002) 1.43
Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism. Ann Clin Biochem (2003) 1.42
An NMR blood test for cancer: a critical assessment. NMR Biomed (1988) 1.42
Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst (2002) 1.33
Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med (1986) 1.29
Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care (2003) 1.22
A computational strategy for the deconvolution of NMR spectra with multiplet structures and constraints: analysis of overlapping 13C-2H multiplets of 13C enriched metabolites from cell suspensions incubated in deuterated media. Magn Reson Med (1996) 1.21
Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects. Biochem J (1984) 1.17
Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.14
NMR spectral quantitation by principal component analysis. NMR Biomed (2001) 1.14
1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma. J Lipid Res (1994) 1.07
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis (2003) 1.01
Metabolites from cerebrospinal fluid in aneurysmal subarachnoid haemorrhage correlate with vasospasm and clinical outcome: a pattern-recognition 1H NMR study. NMR Biomed (2005) 1.00
Quantification of plasma lipids and apolipoproteins by use of proton NMR spectroscopy, multivariate and neural network analysis. NMR Biomed (2000) 0.97
Metabonomic applications in toxicity screening and disease diagnosis. Curr Top Med Chem (2002) 0.95
Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care (2006) 0.92
The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. Atherosclerosis (2006) 0.92
Proton nuclear magnetic resonance-based metabonomics for rapid diagnosis of meningitis and ventriculitis. Clin Infect Dis (2005) 0.88
Sample classification based on Bayesian spectral decomposition of metabonomic NMR data sets. Anal Chem (2004) 0.88
Application of self-organizing maps in conformational analysis of lipids. J Am Chem Soc (2001) 0.87
Independent component analysis to proton spectroscopic imaging data of human brain tumours. Eur J Radiol (2005) 0.87
Independent component analysis for automated decomposition of in vivo magnetic resonance spectra. Magn Reson Med (2003) 0.83
Quantification of biomedical NMR data using artificial neural network analysis: lipoprotein lipid profiles from 1H NMR data of human plasma. NMR Biomed (1995) 0.83
Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism (2004) 0.80
The triglyceride issue revisited. Findings from the Helsinki Heart Study. Arch Intern Med (1995) 0.77
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet (2012) 4.08
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA (2005) 3.01
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes (2009) 2.80
High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst (2009) 2.49
Intensity and coherence of motifs in weighted complex networks. Phys Rev E Stat Nonlin Soft Matter Phys (2005) 2.47
Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med (2011) 2.30
Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care (2005) 2.26
Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care (2011) 2.20
Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol (2010) 2.17
The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care (2011) 2.16
Universal features of correlated bursty behaviour. Sci Rep (2012) 2.10
Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes. Diabetologia (2011) 2.07
Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler Thromb Vasc Biol (2005) 2.07
Leisure-time physical activity and development and progression of diabetic nephropathy in type 1 diabetes: the FinnDiane Study. Diabetologia (2015) 2.05
Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care (2012) 1.98
Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet (2012) 1.97
Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia (2011) 1.90
World citation and collaboration networks: uncovering the role of geography in science. Sci Rep (2012) 1.85
Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol (2011) 1.82
Long-term leisure-time physical activity and serum metabolome. Circulation (2012) 1.81
Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes (2012) 1.80
New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79
Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. Diabetes (2012) 1.78
Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes (2013) 1.71
Impaired vascular dilatation in women with a history of pre-eclampsia. J Hypertens (2006) 1.62
Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circ Cardiovasc Genet (2012) 1.60
Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care (2012) 1.57
On the predictability of future impact in science. Sci Rep (2013) 1.55
A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes (2009) 1.55
Sex differences in intimate relationships. Sci Rep (2012) 1.53
Birth weight is inversely correlated to adult systolic blood pressure and pulse pressure in type 1 diabetes. Hypertension (2004) 1.51
1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol (2008) 1.51
Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol (2013) 1.49
Generalizations of the clustering coefficient to weighted complex networks. Phys Rev E Stat Nonlin Soft Matter Phys (2007) 1.43
Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes--indication of an increased environmental pressure? Diabetologia (2003) 1.41
Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes. Diabetes (2015) 1.40
Many patients with Type 1 diabetes estimate their prandial insulin need inappropriately. J Diabetes (2010) 1.39
Opinions, conflicts, and consensus: modeling social dynamics in a collaborative environment. Phys Rev Lett (2013) 1.39
Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy. Diabetes (2012) 1.36
High-throughput pedigree drawing. Eur J Hum Genet (2005) 1.36
Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care (2005) 1.35
Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease: a note on Mendelian randomization studies. J Am Coll Cardiol (2013) 1.35
Emergence of communities in weighted networks. Phys Rev Lett (2007) 1.33
Temporal motifs reveal homophily, gender-specific patterns, and group talk in call sequences. Proc Natl Acad Sci U S A (2013) 1.31
Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes (2003) 1.29
Serum concentration of cystatin C and risk of end-stage renal disease in diabetes. Diabetes Care (2012) 1.26
Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. BMJ (2011) 1.26
Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab (2005) 1.26
Heritability of proliferative diabetic retinopathy. Diabetes (2008) 1.25
The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol (2008) 1.22
Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci (2011) 1.22